- Home
- XNCR vs PHAR Comparison
XNCR vs PHAR Comparison
Compare XNCR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- PHAR
- Stock Information
- Founded
- XNCR 1997
- PHAR 1988
- Country
- XNCR United States
- PHAR Netherlands
- Employees
- XNCR N/A
- PHAR N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- PHAR Health Care
- Exchange
- XNCR Nasdaq
- PHAR Nasdaq
- Market Cap
- XNCR 1.1B
- PHAR 951.7M
- IPO Year
- XNCR 2013
- PHAR N/A
- Fundamental
- Price
- XNCR $13.86
- PHAR $13.32
- Analyst Decision
- XNCR Buy
- PHAR Strong Buy
- Analyst Count
- XNCR 11
- PHAR 3
- Target Price
- XNCR $24.20
- PHAR $30.00
- AVG Volume (30 Days)
- XNCR 1.5M
- PHAR 10.4K
- Earning Date
- XNCR 11-06-2025
- PHAR 11-06-2025
- Dividend Yield
- XNCR N/A
- PHAR N/A
- EPS Growth
- XNCR N/A
- PHAR N/A
- EPS
- XNCR N/A
- PHAR N/A
- Revenue
- XNCR $146,929,000.00
- PHAR $339,836,000.00
- Revenue This Year
- XNCR $22.09
- PHAR $17.70
- Revenue Next Year
- XNCR N/A
- PHAR $12.25
- P/E Ratio
- XNCR N/A
- PHAR N/A
- Revenue Growth
- XNCR N/A
- PHAR 22.44
- 52 Week Low
- XNCR $6.92
- PHAR $7.31
- 52 Week High
- XNCR $27.24
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- XNCR 55.63
- PHAR 44.89
- Support Level
- XNCR $12.17
- PHAR $13.08
- Resistance Level
- XNCR $15.50
- PHAR $14.10
- Average True Range (ATR)
- XNCR 1.15
- PHAR 0.51
- MACD
- XNCR -0.12
- PHAR -0.13
- Stochastic Oscillator
- XNCR 49.86
- PHAR 16.36
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.